Kendra Meche, NP
Adult Health · Lake Charles, LANPI 1326295239
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 385 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 385 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$701
- Amgen$561
- GSK$513
- Lilly USA, LLC$491
- AstraZeneca$428
- plus $2K from 31 others
What the payments were for
- Food & beverage$6,233100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 84 | $1,217 |
| Novo Nordisk | 45 | $701 |
| Amgen | 43 | $561 |
| GSK | 25 | $513 |
| Lilly USA, LLC | 32 | $491 |
| AstraZeneca | 24 | $428 |
| Novartis | 15 | $247 |
| Sumitomo Pharma America, Inc. | 9 | $212 |
| Amarin Pharma, Inc. | 9 | $192 |
| Boehringer Ingelheim | 11 | $174 |
| Merck | 10 | $165 |
| Exact Sciences | 8 | $154 |
| Bayer | 8 | $149 |
| Pfizer | 8 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $93 |
| Esperion Therapeutics, Inc. | 5 | $76 |
| Axsome Therapeutics, Inc. | 4 | $75 |
| Biohaven Pharmaceuticals, Inc. | 4 | $66 |
| Abbott | 4 | $63 |
| Sunovion Pharmaceuticals Inc. | 6 | $62 |
| Idorsia Pharmaceuticals US Inc | 4 | $59 |
| Dexcom, Inc. | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Johnson & Johnson(2 entities) | 2 | $36 |
| Intuitive Surgical | 1 | $33 |
| Almatica Pharma LLC | 1 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Ardelyx, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
How this compares
$6,233 in reported general payments places this provider in the 85th percentile of 203 adult health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 15 | $14,212 |
| MounjaroTirzepatide | 12 | $12,438 |
| SynthroidLevothyroxine Sodium | 18 | $1,149 |
| Levothyroxine Sodium | 147 | $847 |
| Atorvastatin Calcium | 78 | $672 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 19 | $481 |
| Ezetimibe | 16 | $442 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $439 |
| Simvastatin | 69 | $400 |
| Losartan Potassium | 38 | $361 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 45 | $361 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 38 | $353 |
| Metformin Hcl | 63 | $351 |
| Rosuvastatin Calcium | 18 | $349 |
| Omeprazole | 55 | $348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $701 | $14,21215 claims |
| Lilly USA, LLCMounjaro | $491 | $12,43812 claims |
| AbbVieSynthroid | $1,217 | $1,14918 claims |
| Almatica Pharma LLCSertraline Hcl | $32 | $26440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 203 adult health providers in Louisiana.
Other adult health in Lake Charles
- Damika HarmonLake Charles$27K
- Sarah CoolingLake Charles$10K
- Hollie DonnellyLake Charles$9K
- Amanda BurnettLake Charles$9K
- Jennifer GrahamLake Charles$8K
- Jared WhiteheadLake Charles$6K
- Anna LandryLake Charles$5K
- Rebecca Godare SteinLake Charles$5K
- Jennifer CrawfordLake Charles$5K
- Rachel RowlandLake Charles$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.